logo
Marvell Technology Shares Tumble Despite Strong AI Revenue Growth. Is This an Opportunity to Buy the Dip on a Great Stock?

Marvell Technology Shares Tumble Despite Strong AI Revenue Growth. Is This an Opportunity to Buy the Dip on a Great Stock?

Yahoo11-03-2025

Shares of Marvell Technologies (NASDAQ: MRVL) were plunging following its fiscal 2025 fourth-quarter earnings report, despite the company seeing strong data center and artificial intelligence (AI) revenue growth. The stock is now down more than 40% year to date.
Let's take a closer look at the chipmaker's latest report and guidance to see if this sell-off is a good opportunity to buy the stock.
Marvell is tied to the data center market as it provides networking chips, connectivity solutions, and data storage controllers. As such, it has been benefiting from the AI infrastructure buildout currently taking place. The company also helps customers design their own custom AI chips and provides some intellectual property around Amazon's custom AI chips.
Marvell's strength in this area was seen in Q4, with its data center revenue surging 78% year over year in the quarter to $1.37 billion. The company credited strong demand for its electro-optics products, which are used for high-speed data transmission, and the ramp-up of its custom AI chip program for the strong growth. Data center revenue accounted for 75% of its top line in the quarter.
However, overall revenue climbed just 27% to $1.82 billion as other areas of its business saw steep declines. That result was just ahead of the midpoint of management's guidance. It recorded $171 million in enterprise networking revenue, down 35% over year but up 14% from the third quarter. Carrier infrastructure revenue sank 38% to $106 million but also rose 25% sequentially. Marvell said it was seeing a recovery in both of these markets. Consumer revenue, meanwhile, dropped 38% year over year to $89 million, while automobile revenue rose 4% to $86 million.
Data Center
Networking
Carrier Infrastructure
Consumer
Automobile
Total
Revenue
$1.37 billion
$171 million
$106 million
$89 million
$86 million
$1.82 billion
YOY increase
78%
(35%)
(38%)
(38%)
4%
27%
QOQ increase
24%
14%
25%
(8%)
3%
20%
Data source: Marvell Q4 earnings press release. YOY = year over year. QOQ = quarter on quarter.
Adjusted earnings per share (EPS) climbed 30% year over year to $0.60. That was just ahead of the midpoint of management's outlook of $0.59.
The company generated operating cash flow of $514 million for the quarter and $1.68 billion for the year, which was a record. Marvell repurchased $200 million in stock in the quarter too.
Looking ahead, Marvell guided for fiscal 2026 first-quarter revenue of $1.875 billion, plus or minus 5%, which represents growth of about 60%. It is looking for adjusted EPS of $0.56 to $0.67.
Management said it expects AI revenue to "significantly exceed" its prior $2.5 billion target for fiscal 2026. The company's two leading AI custom programs are in high volume production, and its lead AI accelerator customer is currently working on a next-generation chip. Once it completes its sampling and qualification cycles, it will begin ramping production. Revenue from this customer should grow in the current fiscal year and beyond.
That next-generation chip is a reference to Amazon's Trainium chip, which has been a growing source of uncertainty for investors. Some analysts have reported the possibility that Marvell is losing its place in the partnership to competition, but management's latest remarks should reassure shareholders for the time being.
While Marvell turned in a solid quarter, expectations going into the quarter were high, and the stock's post-earnings sell-off has extended into its third trading day (as of this writing).
Marvell now trades at a forward price-to-earnings (P/E) ratio of just 23 times fiscal 2026 estimates.
That's a much more reasonable valuation compared to where it was trading as recently as January. Meanwhile, it's seeing strong data center and AI revenue growth, and some of its other more cyclical businesses seem to be recovering. The update surrounding its involvement in Amazon's Trainium chip development was overall positive as well.
Macroeconomic uncertainty has only worsened the current sell-off, which looks overdone at this point. With that in mind, investors should consider buying this dip.
Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this.
On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $292,207!*
Apple: if you invested $1,000 when we doubled down in 2008, you'd have $45,326!*
Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $480,568!*
Right now, we're issuing 'Double Down' alerts for three incredible companies, and there may not be another chance like this anytime soon.*Stock Advisor returns as of March 10, 2025
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon. The Motley Fool recommends Marvell Technology. The Motley Fool has a disclosure policy.
Marvell Technology Shares Tumble Despite Strong AI Revenue Growth. Is This an Opportunity to Buy the Dip on a Great Stock? was originally published by The Motley Fool

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RV Camping This Summer? This Power Station With Solar Panels Is at a Record Low Price
RV Camping This Summer? This Power Station With Solar Panels Is at a Record Low Price

Gizmodo

time10 minutes ago

  • Gizmodo

RV Camping This Summer? This Power Station With Solar Panels Is at a Record Low Price

If you're heading out for camping this summer, having a reliable power station is already a smart move. But pairing your power station with a solar panel for true off-grid independence is even better—and right now, the Jackery Solar Generator 300 with a 100W panel is available at a record low price on Amazon, down by 40%. At just $298, this bundle is a steal compared to its original $499 price tag, which makes it one of the best (early Prime Day) deals you'll find for a portable solar power setup. This setup isn't just for summer adventures, either: When storms are closing in and winter looms with a threat of power loss, this power station will keep your essentials charged. See at Amazon At just 7.1 pounds, it's light enough to carry in a backpack but contains a whopping 293Wh lithium-ion battery that can supply up to 300W of clean energy. The device features two pure AC outlets so you can safely power sensitive electronics without risking voltage spikes and interference. If you desire a power station with flexibility, this model is able to charge a maximum of six devices simultaneously. The output diversity is incredible: two AC outlets, a 60W PD USB-C port (input/output compatible), a fast charge 3.0 USB-A port, and a DC car port. Recharging the Jackery Solar Generator 300 is simple: With the wall socket and the 60W PD USB-C port combined, you can top up 80% of the battery in two hours. If you're not stationary, you can use the included car charger cable or simply plug in the 100W panel for clean, green energy. The solar panel will connect with the power station seamlessly, thanks to the onboard MPPT controller. This deal is one of the best you'll find on a trusted brand like Jackery, and with the current discount, it's hard to imagine a better time to invest in this. See at Amazon

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

Business Wire

time12 minutes ago

  • Business Wire

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth. Across nine disclosed programs, the Company anticipates initiating seven Phase 2 or Phase 3 studies during 2025-2026. Acadia further anticipates reporting five Phase 2 or Phase 3 study readouts during 2025-2027—underscoring the breadth of its pipeline and the momentum behind its R&D strategy. Q3 2025 - Phase 2 study initiation for ACP-204 in Lewy Body Dementia Psychosis (LBDP) Q3 2025 - Phase 3 study initiation in Japan for trofinetide in Rett syndrome Early Q4 2025 - Topline results for the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi syndrome (PWS) following the recent completion of enrollment Q4 2025 - Phase 2 study initiation for ACP-211 in major depressive disorder (MDD) Q4 2025 - First in human study of ACP-271 in healthy volunteers Q1 2026 - Potential approval from European Medicines Agency for trofinetide Mid-2026 - Topline results from ACP-204 Phase 2 study in Alzheimer's disease psychosis (ADP) 2026 - Phase 2 study initiation for ACP-711 in Essential Tremor (ET) 'Acadia is building from a position of strength, with two commercial franchises on track to deliver over $1 billion in net sales this year,' said Catherine Owen Adams, Chief Executive Officer. 'As we advance our pipeline, the five molecules we showcase today represent a multibillion-dollar incremental revenue opportunity. They also underscore our unwavering commitment to bold science and our focus on delivering transformative therapies for patients with serious and underserved neurological and rare diseases. We believe the opportunity ahead is extraordinary—and we are confident in our ability to execute with discipline and purpose as we work to build a biotech powerhouse.' 'At Acadia, we're building a strong, sustainable pipeline focused on progressing the most promising science with the goal of meaningfully improving patient care,' said Elizabeth H.Z. Thompson, Ph.D., Executive Vice President, Head of R&D. 'Our pipeline is moving forward with real momentum. Between now and the end of 2026, we plan to initiate seven Phase 2 or 3 studies, with five key readouts anticipated by the end of 2027. We remain deeply committed to advancing care in neurological and rare diseases, leveraging our development expertise and commercial strength to bring meaningful innovation to patients.' The Company will be discussing the following pipeline programs today: ACP-101 (intranasal carbetocin) A long-acting analogue of human oxytocin for the potential treatment of PWS ACP-204 A new, highly selective, potent inverse agonist of 5-HT2A that builds upon lessons learned from pimavanserin for the potential treatment of ADP and LBDP ACP-211 An orally administered, selectively deuterated form of R-Norketamine for the potential treatment of MDD ACP-711 A selective GABA A -α3 modulator targeting the potential treatment of ET ACP-271 A GPR88 agonist for the potential treatment of Tardive Dyskinesia and Huntington's Disease To register for the live webcast, please click here. A replay of Acadia's R&D Day will be available on the company's website, under the investors section for approximately 3 months following the event. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neurological and rare diseases to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as 'may,' 'will,' 'should,' 'could,' 'would,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'predicts,' 'potential,' 'continue,' 'opportunity,' 'goal' and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) our business strategy, objectives and opportunities, including the timing for and clinical and market potential of our pipeline assets, and potential for enhanced shareholder value; (ii) plans for, including timing, development and progress of commercialization or regulatory timelines for our products, including NUPLAZID and DAYBUE, and our product candidates; (iii) benefits to be derived from and efficacy of our products, including the potential advantages of our products and product candidates; (iv) the timing and conduct of and topline results for our clinical trials, including the timing of topline results from our clinical trial in Prader-Willi syndrome, the continuing enrollment in our clinical trials in Alzheimer's disease psychosis, the initiation of our clinical trial in Lewy Body Dementia Psychosis, and the timing and content of our presentations or announcements regarding our clinical trials; (v) our estimates regarding our future financial performance, profitability, capital requirements or expenses, including estimates of potential commercial product and pipeline peak sales and potential net sales of our commercial franchises in 2025, and (vi) our ability to successfully complete additional business development transactions. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our dependency on the continued successful commercialization of our products and our ability to maintain or increase sales of our products; our plans to commercialize DAYBUE globally and trofinetide in the EU; the costs of our commercialization plans and development programs, and the financial impact or revenues from any commercialization we undertake; our ability to obtain necessary regulatory approvals for our product candidates and, if and when approved, market acceptance of our products; the risks inherent with product candidate development, including risks of unsuccessful clinical trial enrollment and negative or inconsistent results; our dependence on third-party collaborators, clinical research organizations, manufacturers, suppliers and distributors; the impact of competitive products and therapies; our ability to generate or obtain the necessary capital to fund our operations; our ability to grow, equip and train our specialized sales forces; our ability to manage the growth and complexity of our organization; our ability to maintain, protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2024 as well as our subsequent filings with the Securities and Exchange Commission from time to time, including our quarterly report on Form 10-Q for the quarter ended March 31, 2025. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.

Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Yahoo

time12 minutes ago

  • Yahoo

Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

SAN DIEGO, June 25, 2025--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced an update on its Phase 1b positron emission tomography (PET) trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor. The Company has completed enrollment of the healthy volunteer and progressive multiple sclerosis (PrMS) cohorts of this trial. The screening and enrollment of idiopathic pulmonary fibrosis (IPF) patients to participate in this trial is ongoing. "In early June, consistent with our protocol, we enrolled two additional PrMS patients to assess PET imaging of the brain," said Timothy Watkins, M.D., Chief Medical Officer and Head of Development, Contineum Therapeutics. "While adding these additional patients to the trial has led to a modest delay in reporting our topline data, we believe the enhanced clinical understanding of PIPE-791 in patients is important to the program. This trial builds on our compelling preclinical data and improves our understanding of receptor occupancy in healthy volunteers and patients, helping guide our dose selection in the next stages of clinical development. We now anticipate reporting topline data from these fully enrolled cohorts in the third quarter of 2025." The Phase 1b, open label, single-center trial is designed to assess the correlation between pharmacokinetics and LPA1 receptor occupancy using PET imaging in healthy volunteers, as well as IPF and PrMS patients. To date, 12 healthy volunteers and four PrMS patients have participated in this trial. More information on this trial can be found at (NCT06683612). About Contineum Therapeutics Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and major depressive disorder. For more information, please visit Forward-Looking Statements Certain statements contained in this press release, other than historical information, constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding the Company's clinical trial and product development plans and timelines, including, but not limited to, those regarding the anticipated timing and results of topline data from the healthy volunteer and PrMS cohorts from the Company's ongoing Phase 1b PET trial; the potential of the Company's Phase 1b PET trial to improve the Company's understanding of target occupancy of PIPE-791 or to guide dose selection for further clinical development, or to predict future clinical outcomes or results; the indications, anticipated benefits of, and market opportunities for its drug candidates; its business strategies and plans; and the quotations of the Company's management. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company's control and may cause its actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties, include, but are not limited to, the following: the Company is heavily dependent on the success of PIPE-791 and PIPE-307, both of which are in the early stages of clinical development, and neither of these drug candidates may progress through clinical development or receive regulatory approval; the results of earlier preclinical studies and clinical trials, including those conducted by third parties, may not be predictive of future results and unexpected adverse side effects or inadequate efficacy of the Company's drug candidates may limit their development, regulatory approval and/or commercialization; the timing and outcome of research, development and regulatory review is uncertain; clinical trials and preclinical studies may not proceed at the time or in the manner expected, or at all; the potential for the Company's programs and prospects to be negatively impacted by developments relating to the Company's competitors, including the results of studies or regulatory determinations relating to the Company's competitors; risks associated with reliance on third parties to successfully conduct clinical trials and, in the case of PIPE-307, the Company's reliance, pursuant to a global license and development agreement, upon Janssen Pharmaceutica NV, a Johnson & Johnson Company, to develop PIPE-307 for any other indication other than relapsing-remitting multiple sclerosis (RRMS) and, after completion of the Company's PIPE-307 Phase 2 VISTA trial, Janssen Pharmaceutica NV's decision, in its sole discretion, whether or not to further develop PIPE-307 for relapsing-remitting multiple sclerosis (RRMS); the Company has incurred significant operating expenses since inception and it expects that its operating expenses will continue to significantly increase for the foreseeable future; the Company's license agreement with Janssen Pharmaceutica NV may not result in the successful development of PIPE-307; the Company may be unable to obtain, maintain and enforce intellectual property protection for its technology and drug candidates; and unstable macroeconomic and market and economic conditions and uncertainty caused by, among other things, geopolitical conditions, tariffs or threatened tariffs, inflation volatility, and military conflict may adversely affect the Company's business and financial condition and the broader economy and biotechnology industry. Additional risks and uncertainties that could affect the Company's business, operations and results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's periodic filings and in other filings that the Company makes with the Securities and Exchange Commission (SEC) from time to time, which are available on the Company's website at under the Investor section and on the SEC's website at Accordingly, readers should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, the Company undertakes no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. View source version on Contacts Steve KunszaboContineum TherapeuticsSenior Director, Investor Relations & Corporate Communications858-649-1158skunszabo@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store